Pioneering Regenerative Medicine
Without Immunosuppression
Pioneering Regenerative Medicine
Without Immunosuppression
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
Developing a Potential Cure for Type 1 Diabetes
Our lead program iTOL-101 is being developed as a potential cure for Type 1 Diabetes and in a pre-clinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our second lead candidate, iTOL-102, is leveraging significant advancements in stem cells to derive pancreatic islets which allows an inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes.
Development Pipeline
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. to Present at the Virtual Investor Pioneering Regenerative Medicine Without Immunosuppression Roundtable Event
Live moderated video webcast roundtable with members of the iTolerance management team to be held on Thursday, October 27th at 3:00 PM ETMIAMI, FL / October 24, 2022 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine company...
iTolerance, Inc. Bolsters Leadership Team with Scientific, Development and Global Regulatory Affairs Expertise
Sumitra Ghate promoted to Senior Vice President of Development & Global Regulatory Affairs to continue driving strategic regulatory and development programsDr. Esma S. Yolcu appointed as Chief Technical Scientist to advance development programs towards IND...
iTolerance and LyGenesis Announce a Joint Research Collaboration to Regrow Functioning, Ectopic Livers Without the Need for Immune Suppression
MIAMI and PITTSBURGH, June 30, 2022 -- iTolerance, Inc., an early-stage regenerative medicine company developing technology to enable tissue, organoid or cell therapy without the need for life-long immunosuppression and LyGenesis, Inc., a clinical-stage biotechnology...